HOME >> BIOLOGY >> NEWS
Tramiprosate (Alzhemed) preclinical results published in Neurobiology of Aging

on and the trial is scheduled to be completed by January 2007. All patients who complete the North American Phase III clinical trial will be offered the opportunity to receive tramiprosate (Alzhemed) in an open-label extension study.

Neurochem is also actively advancing an 18-month Phase III clinical trial for tramiprosate (Alzhemed) in Europe, which was initiated in September 2005. The ongoing European Phase III clinical trial, an international, multi-center, randomized, double-blind, placebo-controlled and parallel-designed study, is progressing on schedule and will investigate the safety, efficacy and disease-modifying potential of tramiprosate (Alzhemed). Some 930 mild-to-moderate AD patients are expected to take part and enrollment is expected to be completed in the fall of 2006.

About Alzheimer's disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a person's cognitive and motor functions, their activities of daily living, alters the behaviour and gradually destroys the brain.

AD is the most common cause of dementia in our aging population. Almost 5 million individuals in the United States alone currently suffer from the condition. The U.S. Alzheimer's Association estimates that by 2025, over 22 million people worldwide will be afflicted.

According to a report commissioned by the U.S. Alzheimer's Association, AD costs American businesses approximately US$61 billion a year. That price tag includes US$24.6 billion for direct health care of Alzheimer's patients and US$36.5 billion to cover costs related to caregivers of AD patients, including lost productivity, absenteeism and worker replacement.


'"/>

Contact: Lise Hébert, PhD
lhebert@neurochem.com
450-680-4570
Neurochem, Inc.
30-May-2006


Page: 1 2 3

Related biology news :

1. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
2. Promising preclinical results with live attenuated H5N1 vaccines
3. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
4. Cytori demonstrates adipose stem cells improve cardiac function in preclinical heart attack model
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ) ... Biometrics Market Forecast and Opportunities, 2020" report ... biometric authentication systems is projected to grow at ... The driving forces for this highly competitive ... and constant development in technology. In 2014, government ...
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
(Date:3/30/2015)... -- US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... Yale University, on March 27 released pre-clinical data on ... an oral presentation by Professor Gil Mor ... nd Annual Scientific Meeting of the Society of ... In both in vitro and in ...
(Date:3/30/2015)... March 30, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... No. 3:13-cv-03494-M and  Spherix v. Uniden , Case ... Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in ...
(Date:3/30/2015)... Richmond Pharmacology nimmt weltweit ... ist das erste Zentrum weltweit, das in Zusammenarbeit ... in London in einer ... an einem Patienten begonnen hat. Das Therapeutikum wurde ... (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... the presentation of important study data showing ... cells in 1,599 gynecologic cancer samples. Using ... tumor profiling service, researchers identified expression of ... gynecologic cancers independent of histology while its ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
Cached News: